Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Ciclosporin Soft Capsules

Research Leaders

6 sponsors active, led by Chinese PLA General Hospital

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Recruiting2
Completed1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT07816874Active Not Recruiting

Model Development and Application Based on Renal Pathology Images

NCT02954419Recruiting

IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

NCT05839314Phase 4Recruiting

Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy

NCT02529722Completed

Biomarkers for the Progression of IgA Nephropathy

Showing all 4 trials

Research Network

Common Treatments

  • Ciclosporin Soft Capsules1
  • Huaier Granule1
  • Reninangiotensinaldosterone System Inhibitors Rasi1
  • No Intervention1

Active Sponsors

  • Chinese PLA General Hospital1
  • Istanbul University1
  • Sun Yat-sen University1
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology1
  • Huazhong University of Science and Technology1

Top Investigators

Related Conditions

  • Iga Nephropathy2
  • Idiopathic Membranous Nephropathy1
  • Membranous Nephropathy1
  • Kidney Diseases Chronic1
  • Nephropathy1

Activity Timeline